OKUR
OnKure Therapeutics Inc. (OKUR)
Market Closed
5 Dec, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
3. 06
+0.43
+16.35%
Pre Market
$
0 0% 3. 06
38.48M Market Cap
- P/E Ratio
0% Div Yield
635,500 Volume
- Eps
$ 2.63
Previous Close Day Range
2.63 3.19
Year Range
1.7 15.89
Want to track OKUR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond
Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-219 has 80X fold improved selectivity PI3K-a targeting versus wild-type PI3K-a, potentially allowing for higher dosing and reducing unwanted off-target effects. The merger with Reneo Pharmaceuticals and $65 million private placement boosts OnKure's cash to $139 million, funding operations into Q4 2026.
Seekingalpha | 1 year ago
2025 © Marketlog. All Rights Reserved.
